The patient presented with history of moderate cytochrome c oxidase-negative muscle fibers, acute elevated circulating hepatic transaminase concentration manifestation, adult onset detected. Subsequent genetic testing revealed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of persistent adult onset. Subsequent genetic testing revealed gene variant Tyr955Cys. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of severe elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with history of persistent cytochrome c oxidase-negative muscle fibers, history of chronic adult onset, clinical signs of persistent seizure. Subsequent genetic testing revealed gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with history of chronic dysarthria. Subsequent genetic testing revealed gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with episodic adult onset, diagnosed with severe dysarthria, mild elevated circulating hepatic transaminase concentration, intermittent seizure observed. Subsequent genetic testing revealed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with intermittent adult onset symptoms, diagnosed with persistent seizure, presence of chronic elevated circulating hepatic transaminase concentration, acute cytochrome c oxidase-negative muscle fibers condition. Subsequent genetic testing revealed gene variant 1399G→A (A467T). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with acute seizure observed. Subsequent genetic testing revealed gene variant c.2864A>G (p.Tyr955Cys). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with episodic cytochrome c oxidase-negative muscle fibers symptoms, clinical signs of chronic seizure. Subsequent genetic testing revealed gene variant 1399G>A A467T and 3573G>T K1191N. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant 1399G >A A467T and 2243G >C W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with chronic adult onset symptoms, episodic seizure observed. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with progressive elevated circulating hepatic transaminase concentration observed. Subsequent genetic testing revealed gene variant 1868T>G  L623W and 2263A>G K755E. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with moderate elevated circulating hepatic transaminase concentration manifestation, progressive dysarthria symptoms, diagnosed with sudden seizure, intermittent adult onset manifestation. Subsequent genetic testing revealed gene variant c.1288A>T and c.2752T>C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with chronic cytochrome c oxidase-negative muscle fibers, episodic dysarthria condition, adult onset symptoms, clinical signs of mild seizure. Subsequent genetic testing revealed gene variant c3239G>C p.Ser1080Thr. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of progressive cytochrome c oxidase-negative muscle fibers, episodic adult onset condition, clinical signs of acute seizure, acute elevated circulating hepatic transaminase concentration detected. Subsequent genetic testing revealed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with severe adult onset condition, clinical signs of acute seizure, diagnosed with progressive cytochrome c oxidase-negative muscle fibers, history of sudden elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant 1399G→A (A467T). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of intermittent cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with chronic dysarthria observed, diagnosed with progressive cytochrome c oxidase-negative muscle fibers, acute seizure manifestation, intermittent adult onset manifestation. Subsequent genetic testing revealed gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with episodic adult onset detected. Subsequent genetic testing revealed gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of persistent dysarthria, diagnosed with persistent seizure, severe adult onset symptoms, presence of progressive cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant 1399G>A A467T and 3573G>T K1191N. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with persistent elevated circulating hepatic transaminase concentration symptoms, persistent adult onset detected, seizure observed. Subsequent genetic testing revealed gene variant c.1156C>T p.R386C and c.2794C>T p.H932Y. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with elevated circulating hepatic transaminase concentration observed, diagnosed with acute seizure, mild dysarthria observed. Subsequent genetic testing revealed gene variant c3239G>C p.Ser1080Thr. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of severe seizure, acute cytochrome c oxidase-negative muscle fibers condition. Subsequent genetic testing revealed gene variant c.1288A>T and c.2752T>C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with progressive dysarthria observed, presence of chronic adult onset, sudden cytochrome c oxidase-negative muscle fibers manifestation. Subsequent genetic testing revealed gene variant P765T. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of acute seizure. Subsequent genetic testing revealed gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with intermittent seizure. Subsequent genetic testing revealed gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with persistent dysarthria detected. Subsequent genetic testing revealed . Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of chronic seizure. Subsequent genetic testing revealed gene variant p.Arg627Gln and p.Arg852Cys. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of acute cytochrome c oxidase-negative muscle fibers, progressive dysarthria manifestation. Subsequent genetic testing revealed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with history of sudden seizure, clinical signs of persistent elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with history of persistent cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed . Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with cytochrome c oxidase-negative muscle fibers manifestation, sudden dysarthria manifestation, clinical signs of episodic adult onset. Subsequent genetic testing revealed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of persistent cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of intermittent seizure, persistent cytochrome c oxidase-negative muscle fibers detected, diagnosed with severe adult onset. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with sudden adult onset symptoms. Subsequent genetic testing revealed gene variant c.3286C>T (p.Arg1096Cys). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with episodic dysarthria manifestation, mild cytochrome c oxidase-negative muscle fibers observed, history of severe elevated circulating hepatic transaminase concentration, clinical signs of moderate adult onset. Subsequent genetic testing revealed gene variant c.2864A>G (p.Tyr955Cys). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with acute seizure manifestation, clinical signs of sudden adult onset, sudden dysarthria condition, episodic cytochrome c oxidase-negative muscle fibers detected. Subsequent genetic testing revealed gene variant C752T (T251I) and C1760T (P587L). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with intermittent elevated circulating hepatic transaminase concentration detected, clinical signs of intermittent seizure. Subsequent genetic testing revealed gene variant Tyr955Cys. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with history of episodic dysarthria, mild adult onset detected, history of sudden cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of moderate adult onset, clinical signs of mild cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant (c.2542G > A) p.G848S and (c.1399G > A) p.A467T. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with episodic cytochrome c oxidase-negative muscle fibers symptoms, history of sudden elevated circulating hepatic transaminase concentration, severe adult onset condition. Subsequent genetic testing revealed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of mild elevated circulating hepatic transaminase concentration, diagnosed with acute seizure, progressive adult onset condition. Subsequent genetic testing revealed gene variant c.2243G>C p.Trp748Ser. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with seizure manifestation, persistent dysarthria, persistent cytochrome c oxidase-negative muscle fibers detected. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with persistent elevated circulating hepatic transaminase concentration detected, chronic dysarthria manifestation. Subsequent genetic testing revealed gene variant p.W748S and p.T914P. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with progressive cytochrome c oxidase-negative muscle fibers symptoms, mild dysarthria, acute adult onset detected. Subsequent genetic testing revealed gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with sudden cytochrome c oxidase-negative muscle fibers symptoms, persistent elevated circulating hepatic transaminase concentration observed. Subsequent genetic testing revealed gene variant R853W and G737R. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with dysarthria observed, intermittent elevated circulating hepatic transaminase concentration condition, adult onset observed. Subsequent genetic testing revealed gene variant p.Arg627Gln and p.Arg852Cys. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with moderate adult onset, clinical signs of moderate cytochrome c oxidase-negative muscle fibers, seizure manifestation. Subsequent genetic testing revealed gene variant T251I/P587L and R807C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with episodic cytochrome c oxidase-negative muscle fibers manifestation, presence of episodic dysarthria, progressive seizure. Subsequent genetic testing revealed gene variant 1399G→A (A467T). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of severe cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant Tyr955Cys. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with severe cytochrome c oxidase-negative muscle fibers, history of mild adult onset, intermittent elevated circulating hepatic transaminase concentration detected, diagnosed with moderate dysarthria. Subsequent genetic testing revealed gene variant p.Arg627Gln and p.Arg852Cys. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with episodic seizure condition, progressive elevated circulating hepatic transaminase concentration manifestation, mild cytochrome c oxidase-negative muscle fibers observed, chronic adult onset. Subsequent genetic testing revealed gene variant c.1535A>T p.K512M. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of severe elevated circulating hepatic transaminase concentration, moderate dysarthria condition, moderate cytochrome c oxidase-negative muscle fibers detected, presence of chronic adult onset. Subsequent genetic testing revealed gene variant R853W and G737R. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with intermittent dysarthria manifestation. Subsequent genetic testing revealed gene variant c.2864A>G (p.Tyr955Cys). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with intermittent cytochrome c oxidase-negative muscle fibers symptoms, acute dysarthria condition, elevated circulating hepatic transaminase concentration manifestation. Subsequent genetic testing revealed gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with history of chronic elevated circulating hepatic transaminase concentration, sudden seizure manifestation, history of intermittent adult onset, progressive cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant 1399G >A A467T and 2243G >C W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with cytochrome c oxidase-negative muscle fibers, presence of moderate seizure. Subsequent genetic testing revealed gene variant W748S and c.3643+2T>C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of severe adult onset, persistent seizure detected, diagnosed with cytochrome c oxidase-negative muscle fibers, elevated circulating hepatic transaminase concentration observed. Subsequent genetic testing revealed gene variant C752T (T251I) and C1760T (P587L). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with progressive cytochrome c oxidase-negative muscle fibers manifestation, clinical signs of severe elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant 1868T>G  L623W and 2263A>G K755E. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with mild dysarthria manifestation, intermittent seizure manifestation, clinical signs of sudden adult onset, episodic elevated circulating hepatic transaminase concentration observed. Subsequent genetic testing revealed gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of progressive elevated circulating hepatic transaminase concentration, clinical signs of chronic cytochrome c oxidase-negative muscle fibers, moderate dysarthria condition, progressive seizure detected. Subsequent genetic testing revealed gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with intermittent dysarthria, episodic elevated circulating hepatic transaminase concentration symptoms, presence of sudden adult onset, episodic cytochrome c oxidase-negative muscle fibers manifestation. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with progressive elevated circulating hepatic transaminase concentration symptoms. Subsequent genetic testing revealed gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of acute dysarthria, cytochrome c oxidase-negative muscle fibers manifestation. Subsequent genetic testing revealed gene variant p.W748S and p.T914P. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with mild seizure observed, episodic cytochrome c oxidase-negative muscle fibers manifestation, clinical signs of episodic elevated circulating hepatic transaminase concentration, clinical signs of progressive adult onset. Subsequent genetic testing revealed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with history of intermittent dysarthria, history of intermittent seizure, chronic adult onset manifestation, severe elevated circulating hepatic transaminase concentration symptoms. Subsequent genetic testing revealed gene variant A467T. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with persistent dysarthria detected, presence of intermittent adult onset. Subsequent genetic testing revealed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with moderate dysarthria detected, mild adult onset manifestation, progressive seizure. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with acute cytochrome c oxidase-negative muscle fibers detected, elevated circulating hepatic transaminase concentration detected, seizure. Subsequent genetic testing revealed gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with progressive seizure symptoms. Subsequent genetic testing revealed gene variant A467T. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with moderate elevated circulating hepatic transaminase concentration, history of chronic seizure, episodic adult onset, cytochrome c oxidase-negative muscle fibers symptoms. Subsequent genetic testing revealed gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with chronic dysarthria observed, moderate cytochrome c oxidase-negative muscle fibers detected. Subsequent genetic testing revealed gene variant c.2243G>C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with progressive seizure, sudden dysarthria condition, progressive elevated circulating hepatic transaminase concentration observed. Subsequent genetic testing revealed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with episodic dysarthria manifestation, presence of acute adult onset, intermittent seizure observed, clinical signs of severe cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant c.2584G>A p.A862T and c.830A>T p.H277L. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with history of acute adult onset. Subsequent genetic testing revealed gene variant c.3102delG (p.Lys1035Serfs*59) and c.3286C>T (p.Arg1096Cys). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with moderate seizure manifestation, severe dysarthria manifestation, progressive elevated circulating hepatic transaminase concentration manifestation, diagnosed with intermittent cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with acute dysarthria symptoms, sudden seizure manifestation, episodic adult onset detected, cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with progressive elevated circulating hepatic transaminase concentration observed. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of sudden elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant p.Arg627Gln and p.Arg852Cys. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with moderate elevated circulating hepatic transaminase concentration observed, moderate dysarthria condition, episodic adult onset condition. Subsequent genetic testing revealed . Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with episodic cytochrome c oxidase-negative muscle fibers condition. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with intermittent elevated circulating hepatic transaminase concentration observed, clinical signs of moderate adult onset. Subsequent genetic testing revealed gene variant 1399G >A A467T and 2243G >C W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of intermittent elevated circulating hepatic transaminase concentration, history of chronic adult onset, history of moderate dysarthria, clinical signs of severe cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant c.2243G>C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with acute dysarthria manifestation. Subsequent genetic testing revealed gene variant C752T (T251I) and C1760T (P587L). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with moderate elevated circulating hepatic transaminase concentration manifestation, acute cytochrome c oxidase-negative muscle fibers condition, chronic adult onset symptoms. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with persistent elevated circulating hepatic transaminase concentration, dysarthria detected, progressive cytochrome c oxidase-negative muscle fibers observed. Subsequent genetic testing revealed . Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with moderate dysarthria manifestation, adult onset observed, presence of intermittent seizure. Subsequent genetic testing revealed gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with chronic adult onset. Subsequent genetic testing revealed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with moderate cytochrome c oxidase-negative muscle fibers detected. Subsequent genetic testing revealed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with episodic adult onset manifestation, history of mild elevated circulating hepatic transaminase concentration, progressive cytochrome c oxidase-negative muscle fibers detected. Subsequent genetic testing revealed . Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with acute cytochrome c oxidase-negative muscle fibers detected, episodic seizure condition, moderate elevated circulating hepatic transaminase concentration detected. Subsequent genetic testing revealed gene variant R853W and G737R. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with intermittent seizure detected, sudden dysarthria observed, mild cytochrome c oxidase-negative muscle fibers detected. Subsequent genetic testing revealed gene variant p.W748S and p.T914P. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with mild cytochrome c oxidase-negative muscle fibers symptoms, acute adult onset manifestation, history of intermittent dysarthria. Subsequent genetic testing revealed gene variant c.3286C>T (p.Arg1096Cys). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of acute seizure, diagnosed with mild dysarthria. Subsequent genetic testing revealed gene variant 1399G→A (A467T). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of severe elevated circulating hepatic transaminase concentration, intermittent seizure observed, intermittent adult onset manifestation, history of intermittent cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant 1399G→A (A467T). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with moderate dysarthria. Subsequent genetic testing revealed gene variant A467T. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with acute seizure manifestation, persistent elevated circulating hepatic transaminase concentration observed, acute dysarthria condition. Subsequent genetic testing revealed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with progressive dysarthria, cytochrome c oxidase-negative muscle fibers condition, episodic adult onset. Subsequent genetic testing revealed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with history of persistent cytochrome c oxidase-negative muscle fibers, severe adult onset detected, mild seizure symptoms, diagnosed with dysarthria. Subsequent genetic testing revealed gene variant c.2243G>C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of progressive elevated circulating hepatic transaminase concentration, seizure condition, history of mild adult onset. Subsequent genetic testing revealed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of progressive elevated circulating hepatic transaminase concentration, adult onset observed, intermittent dysarthria observed. Subsequent genetic testing revealed gene variant c.1535A>T p.K512M. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with severe dysarthria symptoms, adult onset detected, moderate seizure condition, mild elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with severe cytochrome c oxidase-negative muscle fibers symptoms. Subsequent genetic testing revealed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with severe adult onset observed, sudden elevated circulating hepatic transaminase concentration symptoms. Subsequent genetic testing revealed gene variant R853W and G737R. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of moderate elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant p.Arg953Cys. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with mild cytochrome c oxidase-negative muscle fibers detected, mild seizure observed. Subsequent genetic testing revealed gene variant 1868T>G  L623W and 2263A>G K755E. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with intermittent cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant 1399G→A (A467T). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with severe cytochrome c oxidase-negative muscle fibers, clinical signs of mild adult onset. Subsequent genetic testing revealed gene variant C752T (T251I) and C1760T (P587L). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with acute seizure condition, diagnosed with chronic adult onset, dysarthria symptoms. Subsequent genetic testing revealed gene variant R853W and G737R. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with intermittent adult onset, clinical signs of moderate dysarthria, history of moderate elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed . Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of moderate cytochrome c oxidase-negative muscle fibers, clinical signs of severe adult onset. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with chronic seizure manifestation. Subsequent genetic testing revealed gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with chronic seizure. Subsequent genetic testing revealed gene variant R853W and G737R. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of episodic dysarthria, seizure observed, sudden cytochrome c oxidase-negative muscle fibers observed. Subsequent genetic testing revealed gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with sudden elevated circulating hepatic transaminase concentration, mild adult onset observed, seizure observed, persistent dysarthria detected. Subsequent genetic testing revealed gene variant c.2243G>C p.Trp748Ser. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of seizure, acute cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant c.2864A>G (p.Tyr955Cys). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with persistent cytochrome c oxidase-negative muscle fibers detected, dysarthria observed, history of episodic elevated circulating hepatic transaminase concentration, presence of seizure. Subsequent genetic testing revealed gene variant 1868T>G  L623W and 2263A>G K755E. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with progressive seizure observed, history of mild adult onset. Subsequent genetic testing revealed gene variant c. 2243G>C (p. W748S). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with persistent adult onset, episodic elevated circulating hepatic transaminase concentration symptoms, dysarthria, intermittent cytochrome c oxidase-negative muscle fibers condition. Subsequent genetic testing revealed gene variant c.1399G>A (p.A467T) and c.3285C>G (p.S1095R). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with history of persistent cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant R853W and G737R. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with history of severe cytochrome c oxidase-negative muscle fibers, sudden seizure. Subsequent genetic testing revealed gene variant c.2243G>C p.Trp748Ser. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with seizure detected, mild dysarthria detected, diagnosed with mild elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with sudden adult onset condition, presence of acute elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant c.1288A>T and c.2752T>C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with mild adult onset manifestation, progressive elevated circulating hepatic transaminase concentration manifestation. Subsequent genetic testing revealed gene variant W748S and c.3643+2T>C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with episodic adult onset condition, clinical signs of moderate cytochrome c oxidase-negative muscle fibers, dysarthria observed, sudden seizure detected. Subsequent genetic testing revealed gene variant c. 2243G>C (p. W748S). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with cytochrome c oxidase-negative muscle fibers detected, clinical signs of episodic elevated circulating hepatic transaminase concentration, clinical signs of mild seizure, sudden dysarthria condition. Subsequent genetic testing revealed gene variant A467T. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with progressive dysarthria observed, history of persistent cytochrome c oxidase-negative muscle fibers, diagnosed with moderate elevated circulating hepatic transaminase concentration, mild adult onset detected. Subsequent genetic testing revealed . Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of chronic seizure, clinical signs of moderate adult onset, presence of severe cytochrome c oxidase-negative muscle fibers, progressive elevated circulating hepatic transaminase concentration symptoms. Subsequent genetic testing revealed gene variant c.3286C>T (p.Arg1096Cys). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of moderate seizure, intermittent cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with progressive seizure symptoms. Subsequent genetic testing revealed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with persistent dysarthria observed. Subsequent genetic testing revealed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with history of moderate seizure, diagnosed with persistent cytochrome c oxidase-negative muscle fibers, diagnosed with intermittent dysarthria. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with episodic adult onset symptoms, persistent seizure observed, history of mild elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant c.3311C>G (p.S1104C) and c.2542G>A (p.G848S). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with severe dysarthria, chronic elevated circulating hepatic transaminase concentration manifestation. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with persistent elevated circulating hepatic transaminase concentration detected. Subsequent genetic testing revealed gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with intermittent elevated circulating hepatic transaminase concentration, history of episodic seizure. Subsequent genetic testing revealed gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with sudden elevated circulating hepatic transaminase concentration condition, persistent cytochrome c oxidase-negative muscle fibers detected, history of intermittent dysarthria, chronic seizure manifestation. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with moderate dysarthria manifestation, presence of progressive elevated circulating hepatic transaminase concentration, severe adult onset observed, presence of mild seizure. Subsequent genetic testing revealed gene variant 1399G >A A467T and 2243G >C W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of acute seizure, diagnosed with severe adult onset, intermittent cytochrome c oxidase-negative muscle fibers condition. Subsequent genetic testing revealed gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with acute dysarthria. Subsequent genetic testing revealed gene variant A467T. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of intermittent cytochrome c oxidase-negative muscle fibers, acute elevated circulating hepatic transaminase concentration detected. Subsequent genetic testing revealed gene variant c. 2243G>C (p. W748S). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with episodic dysarthria condition. Subsequent genetic testing revealed gene variant W748S and c.3643+2T>C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with persistent dysarthria observed, presence of sudden adult onset, chronic elevated circulating hepatic transaminase concentration, sudden seizure manifestation. Subsequent genetic testing revealed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with episodic elevated circulating hepatic transaminase concentration manifestation, adult onset symptoms, clinical signs of dysarthria. Subsequent genetic testing revealed gene variant P765T. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with elevated circulating hepatic transaminase concentration symptoms. Subsequent genetic testing revealed gene variant W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of acute elevated circulating hepatic transaminase concentration, intermittent adult onset symptoms, severe dysarthria. Subsequent genetic testing revealed gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with cytochrome c oxidase-negative muscle fibers, sudden elevated circulating hepatic transaminase concentration detected, severe seizure detected. Subsequent genetic testing revealed . Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with sudden elevated circulating hepatic transaminase concentration, seizure, diagnosed with moderate dysarthria. Subsequent genetic testing revealed gene variant A467T. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with progressive dysarthria condition. Subsequent genetic testing revealed gene variant c.2993C>T p.998S>L and c.3550G>C p.1184D>H. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with history of moderate dysarthria, seizure, progressive cytochrome c oxidase-negative muscle fibers manifestation. Subsequent genetic testing revealed gene variant c.1399G>A p.Ala467Thr and c.2542G>A p.Gly848Ser. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with moderate cytochrome c oxidase-negative muscle fibers detected, presence of intermittent adult onset, presence of chronic elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant T251I/P587L and R807C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with intermittent dysarthria detected, clinical signs of mild adult onset, sudden cytochrome c oxidase-negative muscle fibers condition. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with episodic adult onset, moderate seizure detected, clinical signs of mild elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with sudden seizure, history of persistent elevated circulating hepatic transaminase concentration, moderate cytochrome c oxidase-negative muscle fibers observed, acute dysarthria symptoms. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with history of episodic adult onset, diagnosed with persistent elevated circulating hepatic transaminase concentration, clinical signs of moderate cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of episodic seizure, clinical signs of chronic adult onset, mild elevated circulating hepatic transaminase concentration detected. Subsequent genetic testing revealed gene variant T251I/P587L and R807C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of severe adult onset, chronic elevated circulating hepatic transaminase concentration symptoms, progressive seizure manifestation. Subsequent genetic testing revealed gene variant 1399G→A (A467T). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with severe dysarthria, diagnosed with elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant W748S and 15q26 118 kb deletion involving POLG1 gene and FANCI gene. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with diagnosed with sudden seizure, history of chronic cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant A467T. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with elevated circulating hepatic transaminase concentration detected, acute seizure observed, acute cytochrome c oxidase-negative muscle fibers observed. Subsequent genetic testing revealed gene variant R853W and G737R. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with moderate cytochrome c oxidase-negative muscle fibers observed, intermittent dysarthria symptoms, presence of chronic elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant p.Arg953Cys. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with episodic dysarthria manifestation, mild seizure manifestation, presence of sudden adult onset, mild elevated circulating hepatic transaminase concentration symptoms. Subsequent genetic testing revealed gene variant (c.2542G > A) p.G848S and (c.1399G > A) p.A467T. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with cytochrome c oxidase-negative muscle fibers observed, moderate adult onset observed, elevated circulating hepatic transaminase concentration observed. Subsequent genetic testing revealed gene variant R853W and G737R. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of mild cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant c.752C>T (p.T251I) and c.2542G>A (p.G848S). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of persistent adult onset, history of sudden dysarthria, diagnosed with moderate elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed . Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with sudden dysarthria detected, mild elevated circulating hepatic transaminase concentration condition. Subsequent genetic testing revealed . Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with chronic cytochrome c oxidase-negative muscle fibers symptoms. Subsequent genetic testing revealed gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of episodic dysarthria. Subsequent genetic testing revealed gene variant p.Arg953Cys. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with mild elevated circulating hepatic transaminase concentration observed, diagnosed with seizure, clinical signs of intermittent dysarthria. Subsequent genetic testing revealed gene variant c.752C>T (p.Thr251Ile) and c.1760C>T (p.Pro587Leu). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with moderate adult onset manifestation, presence of progressive seizure, progressive cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant c911T > G (p. L304R) and 3240-3242 duplication (pR1081dup). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with chronic cytochrome c oxidase-negative muscle fibers, episodic seizure, diagnosed with acute elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with persistent elevated circulating hepatic transaminase concentration condition. Subsequent genetic testing revealed gene variant A467T. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of mild dysarthria, clinical signs of sudden seizure, sudden cytochrome c oxidase-negative muscle fibers manifestation. Subsequent genetic testing revealed gene variant A467T. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of acute elevated circulating hepatic transaminase concentration, sudden dysarthria manifestation, history of cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant p.W748S and p.T914P. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with acute elevated circulating hepatic transaminase concentration manifestation, history of seizure. Subsequent genetic testing revealed gene variant c.1535A>T p.K512M. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with sudden seizure. Subsequent genetic testing revealed gene variant c.1399G>A p.Ala467Thr and c.3626_3629dupGATA. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with dysarthria observed, progressive cytochrome c oxidase-negative muscle fibers manifestation, moderate adult onset, history of intermittent seizure. Subsequent genetic testing revealed gene variant 1399G→A (A467T). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with sudden cytochrome c oxidase-negative muscle fibers symptoms, clinical signs of persistent elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant C752T (T251I) and C1760T (P587L). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with mild adult onset condition. Subsequent genetic testing revealed gene variant c.1535A>T p.K512M. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with severe seizure symptoms, history of cytochrome c oxidase-negative muscle fibers, moderate adult onset observed, clinical signs of dysarthria. Subsequent genetic testing revealed gene variant c.2554C>T (p.R852C) and c.32G>A (p.G11D). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with intermittent dysarthria observed, chronic seizure, clinical signs of intermittent elevated circulating hepatic transaminase concentration. Subsequent genetic testing revealed gene variant c.1288A>T and c.2752T>C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with moderate cytochrome c oxidase-negative muscle fibers condition. Subsequent genetic testing revealed gene variant c.752C>T (p.T251I) and c.3572A>G (p.K1191R). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with progressive elevated circulating hepatic transaminase concentration condition, moderate seizure observed. Subsequent genetic testing revealed gene variant c3239G>C p.Ser1080Thr. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with sudden adult onset manifestation. Subsequent genetic testing revealed gene variant p.Arg1096His (c.3287G>A) and p.Arg953Cys (c.2857C>T). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with sudden dysarthria detected, diagnosed with severe cytochrome c oxidase-negative muscle fibers, clinical signs of intermittent adult onset, mild seizure observed. Subsequent genetic testing revealed gene variant c.2243G>C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with dysarthria detected, progressive seizure observed. Subsequent genetic testing revealed gene variant c.679C>T p.R227W and c.2542G>A p.G848S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with mild adult onset observed, history of chronic elevated circulating hepatic transaminase concentration, intermittent dysarthria condition, sudden seizure manifestation. Subsequent genetic testing revealed gene variant p.Arg627Gln and p.Arg852Cys. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with seizure observed, elevated circulating hepatic transaminase concentration observed, dysarthria symptoms. Subsequent genetic testing revealed gene variant W748S and c.3643+2T>C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with chronic elevated circulating hepatic transaminase concentration manifestation, intermittent cytochrome c oxidase-negative muscle fibers, clinical signs of chronic adult onset. Subsequent genetic testing revealed gene variant 1399G>A A467T and 3573G>T K1191N. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with mild adult onset symptoms, seizure detected, intermittent cytochrome c oxidase-negative muscle fibers, history of episodic dysarthria. Subsequent genetic testing revealed gene variant T251I/P587L and R807C. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with severe adult onset observed. Subsequent genetic testing revealed gene variant 1399G >A A467T and 2243G >C W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with chronic cytochrome c oxidase-negative muscle fibers manifestation, persistent dysarthria symptoms, acute adult onset condition. Subsequent genetic testing revealed gene variant p.A467T and c.2157+5_6GC>AG. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with clinical signs of persistent dysarthria, sudden elevated circulating hepatic transaminase concentration condition, presence of mild cytochrome c oxidase-negative muscle fibers. Subsequent genetic testing revealed gene variant p.A467T and c.2157+5_6GC>AG. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with severe cytochrome c oxidase-negative muscle fibers symptoms, diagnosed with mild seizure, acute elevated circulating hepatic transaminase concentration observed. Subsequent genetic testing revealed gene variant c.1288A>T p.M430L and c.2752T>C p.W918R. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with history of severe dysarthria, history of severe adult onset, history of moderate seizure. Subsequent genetic testing revealed gene variant p.A467T (c.1399G>A) and 4740 bp deletion (87,662,161 to 87,666,900 or c.2426 + 77 to c.3483 − 390) in the long arm of chromosome 15, spanning intron 14 to intron 21 of the POLG gene. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with persistent cytochrome c oxidase-negative muscle fibers observed. Subsequent genetic testing revealed gene variant c.3643+1G>A and c.2396C>A (p.S799Y). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of cytochrome c oxidase-negative muscle fibers, severe adult onset, clinical signs of intermittent elevated circulating hepatic transaminase concentration, severe seizure observed. Subsequent genetic testing revealed gene variant c. 2243G>C (p. W748S). Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
The patient presented with presence of persistent cytochrome c oxidase-negative muscle fibers, history of episodic elevated circulating hepatic transaminase concentration, episodic seizure symptoms, history of chronic dysarthria. Subsequent genetic testing revealed gene variant A467T and W748S. Over the past few months, the symptoms have evolved, prompting the clinical team to initiate targeted therapy and recommend ongoing monitoring.
